SRXHConsumer Defensive · Packaged Foods

SRXH Stock Forecast: SRX Global, Inc. Price Predictions for 2026-2027

Last close, 13 Nov 2026
$0.95

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 3 of 100 as at 14 Nov 2026 — in the weakest quartile.

Market cap
$19.2M
Ticker Nerd rank
3/ 100
Median analyst target
—
Analysts covering
—
Revenue$3.4M
Operating income−$3.2M
Net income−$4.1M
Free cash flow−$956K
Quarterly, 7 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

SRXH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores SRX Global, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Nov 2026
3/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
87
Revisions
25
Issuance
21
Momentum
20
Volatility
12
Accruals
7
Quality
2
Value
2
Growth
1

Size (87): Smaller than most of the companies we track.

Growth (1): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

SRXH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SRXH, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

SRXH appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Estimates

SRXH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

SRX Global, Inc. (SRXH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 75% of US stocks

Price / sales
2.9×

Cheaper than 39% of US stocks

Price / book
0.1×

Cheaper than 89% of US stocks

EV / EBITDA
2.3×

Cheaper than 57% of US stocks

Growth & margins
Revenue growth (YoY)
−1.4%

Higher than 26% of US stocks

Earnings growth (YoY)
−52.0%

Higher than 11% of US stocks

Gross margin
26.7%

Higher than 29% of US stocks

Operating margin
−122.6%

Higher than 13% of US stocks

Net margin
23.4%

Higher than 84% of US stocks

Returns & dividend
Return on equity
−11058.0%

Higher than 1% of US stocks

Return on assets
−535.7%

Higher than 1% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

SRX Global, Inc. (SRXH) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • SRX Global, Inc. has a market value of $19.2M and an enterprise value of −$26.5M.

  • Revenue in the twelve months to 30 June 2026: −$24.9M. The latest quarter shrank 1.4% year on year.

  • Net income over the same four quarters: −$34.4M, a 138.1% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$2.9M.

  • Shares outstanding: 14.3M.

  • Trailing P/E: 0.0×.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • SRX Global, Inc. employs 7 people — −$3.6M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Nov 2026

Data provided by Twelve Data

Peers

SRXH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelPackaged Foods
CompanyMarket capTKN rank
SRXHSRX Global, Inc.$19.2M3
COOTAustralian Oilseeds Holdings Ltd.$19.1M8
BRLSBorealis Foods, Inc.$20.6M50
HAINThe Hain Celestial Group, Inc.$12.7M53
LSFLaird Superfood, Inc.$27.7M21
JVACoffee Holding Co., Inc.$28.9M98
BHSTBioHarvest Sciences, Inc.$34.1M33

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own SRX Global, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SRXH news & analysis

SRX Global Provides Update on Balance Sheet and Share Buyback

GlobeNewsWire · 30 Oct 2026neutral

SRX Global announced that it is providing shareholders with an update on its balance sheet and share buyback.

Why it matters — The update may provide SRXH watchers with information about the company’s balance sheet and share-buyback plans.

SRX Global Announces Activation of the University of California, Davis as a Clinical Trial Site for CERo Therapeutics' Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies

GlobeNewsWire · 26 Oct 2026positive

SRX Global announced that UC Davis has been activated as a clinical trial site for CERo Therapeutics’ ongoing Phase 1 CERTAIN-T trial of CER-1236 in hematologic malignancies. UC Davis is also CER-1236’s primary manufacturing site; activation is expected to expand patient recruitment capacity and streamline treatment logistics.

Why it matters — The announcement links SRX Global to an additional trial site and operational capacity for CERo Therapeutics’ ongoing study.

SRX Global Commits $2.5 Million to Launch Multi-Strategy Trading Platform in Partnership with 5T Trading, Powered by the EMJX Platform

GlobeNewsWire · 8 Oct 2026positive

SRX Global said it will commit $2.5 million to launch a multi-strategy trading platform in partnership with 5T Trading, powered by the EMJX platform. The launch is planned with managers from Millennium Management, Balyasny and Citadel under Eric Jackson’s leadership.

Why it matters — The announcement outlines a new SRXH-backed trading platform and its planned leadership and partnerships.

SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancies

GlobeNewsWire · 7 Oct 2026positive

SRX Global and its wholly owned SPV, CERO 1236, entered a definitive agreement to acquire CERo Therapeutics, which is developing the CER-1236 cellular immunotherapy candidate for hematologic malignancies. The SPV is intended to raise capital directly at the subsidiary level without diluting existing SRX Global shareholders.

Why it matters — The proposed acquisition would bring CERo Therapeutics under SRX Global and is described as intended to accelerate development of its lead candidate.

SRX Global Commits $1.5 Million to Launch Family of AI-Powered ETFs through its EMJX Platform, Partnering with Kupa AI Co-Founder Andy Kim

GlobeNewsWire · 6 Oct 2026positive

SRX Global committed $1.5 million to launch a family of actively managed ETFs through its EMJX platform. The initial ETF is planned to feature an AI-powered digital-asset hedging strategy.

Why it matters — The commitment marks SRX’s announced move to bring EMJX’s proprietary AI-driven investment technology into an ETF offering.

FAQ

Frequently asked questions about SRXH stock

How does Ticker Nerd's model rank SRXH?

As at 14 Nov 2026, SRX Global, Inc. ranks 3 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (87 of 100).

What is the SRXH stock forecast for 2030?

No analyst covering SRX Global, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SRXH are extrapolating price history, which says nothing about the business.

What does SRX Global, Inc. do?

SRx Health Solutions Inc. is a healthcare services company focused on specialty pharmacy care, clinic services, and patient support across Canada.

What is the latest news on SRXH?

The most recent item we track (GlobeNewsWire, 30 Oct 2026): "SRX Global Provides Update on Balance Sheet and Share Buyback". SRX Global announced that it is providing shareholders with an update on its balance sheet and share buyback.

Company

About SRX Global, Inc.

SRx Health Solutions Inc. is a healthcare services company focused on specialty pharmacy care, clinic services, and patient support across Canada. The company operates an integrated network that includes specialty pharmacies, infusion and injection clinics, clinical trial sites, pharmacy wholesale and distribution, nursing services, and allied health support. Its offerings cover medication management, vaccination services, compounding, diabetes care, travel health, and other specialized treatment programs designed to support patients with complex or ongoing needs. SRx Health Solutions also serves healthcare providers and institutions through collaborative service models that connect pharmacies, clinics, and support programs. In addition, the company operates a pet health and wellness business under the Halo brand, offering foods, treats, chews, dental products, and supplements for dogs and cats. The business plays a role in specialty healthcare delivery by combining clinical services, pharmaceutical operations, and wellness products in one platform.

CEO Dr. Eric M. Jackson Ph.D. · 7 employees · United States · https://www.srxglobalinc.com